Rescue of streptomycin activity by piperine in Mycobacterium tuberculosis

Papers of special note have been highlighted as: • of interest

References

• 1. Global tuberculosis report 2020. Geneva: World Health Organization (2020). http://www.who.int/publications/i/item/9789240013131
  Google Scholar
• 2. Cade CE, Dlouhy AC, Medzihradszky KF, Salas-Castillo SP, Ghiladi RA. Isoniazid-resistance confering mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities. Protein Sci. 19(3), 458–474 (2010).
  Medline CASGoogle Scholar
• 3. Malinga LA, Stoltz A, Martie A, Walt M. Efflux pump mediated second-line tuberculosis drug resistance. Mycobact. Dis. 6(3), 2161–1068 (2016).
  Google Scholar
• 4. Jagielski T, Ignatowska H, Bakuła Z et al. Screening for streptomycin resistance-conferring mutations in Mycobacterium tuberculosis clinical isolates from Poland. PLoS ONE 9(6), 1–8 (2014).
  Google Scholar
• 5. Sharma D, Bisht D. Secretory proteome analysis of streptomycin-resistant Mycobacterium tuberculosis clinical isolates. SLAS Discov. 22(10), 1229–1238 (2017).
  Medline CASGoogle Scholar
• 6. Motta SS, Cluzel P, Aldana M. Adaptive resistance in bacteria requires epigenetic inheritance, genetic noise, and cost of efflux pumps. PLoS ONE 10(3), 1–18 (2015).
  Google Scholar
• 7. Szumowski JD, Adams KN, Edelstein PH, Ramakrishnan L. Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations. Curr. Top. Microbiol. Immunol. 374, 1–25 (2013).
  MedlineGoogle Scholar
• 8. Sharma A, Gupta VK, Pathania R. Efflux pump inhibitors for bacterial pathogens: from bench to bedside. Indian J. Med. Res. 149(2), 129–145 (2019).
  Medline CASGoogle Scholar
• 9. Wadhwa S, Singhal S, Rawat S. Bioavailability enhancement by piperine: a review. Asian J. Biomed. Pharm. Sci. 4(36), 1–8 (2014).
  Google Scholar
• 10. Zhai WJ, Zhang ZB, Xu NN, Guo YF, Qiu C. Piperine plays an anti-inflammatory role in Staphylococcus aureus endometritis by inhibiting activation of NF-κB and MAPK pathways in mice. Evid. Based Complement. Alternat. Med. 2016, 1–10 (2016).
  Google Scholar
• 11. Rani SKS, Saxena N. Udaysree. Antimicrobial activity of black pepper (Piper nigrum L.). Global J. Pharmacol. 7(1), 87–90 (2013).
  Google Scholar
• 12. Moon YS, Choi WS, Park ES et al. Antifungal and antiaflatoxigenic methylenedioxy-containing compounds and piperine-like synthetic compounds. Toxins (Basel) 8(8), 240–250 (2016).
  Google Scholar
• 13. Parmar VS, Jain SC, Bisht KS et al. Phytochemistry of the genus Piper. Phytochemistry. 46(4), 597–673 (1997).
  CASGoogle Scholar
• 14. Khajuria A, Thusu N, Zutshi U, Bedi KL. Piperine modulation of carcinogen induced oxidative stress in intestinal mucosa. Mol. Cell. Biochem. 189(1-2), 113–118 (1998).
  Medline CASGoogle Scholar
• 15. Sharma S, Kumar M, Sharma S, Nargotra A, Koul S. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 65(8), 1694–1701 (2010). • Prior studies had shown synergistic activity between piperine and classical antituberculosis drugs.
  Medline CASGoogle Scholar
• 16. Supply P, Allix C, Lesjean S et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J. Clin. Microbiol. 44, 4498–4510 (2006).
  Medline CASGoogle Scholar
• 17. Molhuizem HOF, Bunschoeten AE, Schouls LM, Van Embden JDA. Rapid detection and simultaneous strain differentiation of Mycobacterium tuberculosis complex bacteria by spoligotyping. Methods Mol. Biol. 101, 381–394 (1998).
  MedlineGoogle Scholar
• 18. Caleffi-Ferracioli K, Cardoso RF, Souza JVP et al. Modulatory effects of verapamil in rifampicin activity against Mycobacterium tuberculosis. Future Microbiol. 14(3), 185–194 (2019).
  CASGoogle Scholar
• 19. European Centre for Disease Prevention and Control. First- and second-line drug susceptibility testing for Mycobacterium tuberculosis complex. In: Handbook on Tuberculosis Laboratory Diagnostic Methods in the European Union – Updated 2018. ECDC, Stockholm, Sweden (2018).
  Google Scholar
• 20. Palomino JC, Martin A, Camacho M et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46(8), 2720–2722 (2002). • Describes one of the main methodologies to determine the minimal inhibitory concentration drug.
  Medline CASGoogle Scholar
• 21. Caleffi-Ferracioli KR, Maltempe FG, Siqueira VLD et al. Fast detection of drugs interaction in Mycobacterium tuberculosis by checkerboard resazurin method. Tuberculosis (Edinb.) 93(6), 660–663 (2013). • The resazurin drugs combination microtiter technique was a pioneer in studying the evolving drugs in combination.
  Medline CASGoogle Scholar
• 22. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52(1), 1 (2003).
  Medline CASGoogle Scholar
• 23. Coelho T, Machado D, Couto I et al. Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil. Front. Microbiol. 6, 1–12 (2015).
  MedlineGoogle Scholar
• 24. Gröblacher B, Kunert O, Bucar F. Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis. Bioorg. Med. Chem. 20, 2701–2706 (2012). • Reference article for the modulation factor calculation.
  MedlineGoogle Scholar
• 25. Campanerut PAZ, Ghiraldi LD, Spositto FLE et al. Rapid detection of resistance to pyrazinamide in Mycobacterium tuberculosis using the resazurin microtiter assay. J. Antimicrob. Chemother. 66(5), 1044–1046 (2011).
  Medline CASGoogle Scholar
• 26. Caleffi-Ferracioli KR, Amaral RCR, Demitto FO et al. Morphological changes and differentially expressed efflux pump genes in Mycobacterium tuberculosis exposed to a rifampicin and verapamil combination. Tuberculosis (Edinb.) 97, 65–72 (2016). • Describes a pioneer study evaluating the differentially expressed efflux pump genes in Mycobacterium tuberculosis H37Rv exposed to rifampicin and verapamil combination.
  Medline CASGoogle Scholar
• 27. Wang K, Pei H, Huang B et al. The expression of ABC efflux pump, Rv1217c–Rv1218c, and its association with multidrug resistance of Mycobacterium tuberculosis in China. Curr. Microbiol. 66(3), 222–226 (2013).
  Medline CASGoogle Scholar
• 28. Rodrigues L, Machado D, Couto I, Amaral L, Viveiros M. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect. Genet. Evol. 12, 695–700 (2012).
  Medline CASGoogle Scholar
• 29. Rossi E, Aínsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol. Rev. 30(1), 36–52 (2006).
  MedlineGoogle Scholar
• 30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using Real-Time quantitative PCR and the -ΔΔCt method. Methods 25(4), 402–408 (2001).
  Medline CASGoogle Scholar
• 31. Arbex MA, Varella MCL, Siqueira HR, Mello FAF. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J. Bras. Pneumol. 36(5), 626–640 (2010).
  MedlineGoogle Scholar
• 32. Wellington S, Hung DT. The expanding diversity of Mycobacterium tuberculosis drug targets. ACS Infect. Dis. 4(5), 696–714 (2018).
  Medline CASGoogle Scholar
• 33. Echeverria-Valencia G, Flores-Villalva S, Espitia CI. Virulence factors and pathogenicity of Mycobacterium tuberculosis. In: Mycobacterium-Research and Development. IntechOpen, 231–255 (2018).
  Google Scholar
• 34. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetic by pirazinoic acid. J. Antimicrob. Chemother. 52(5), 790–795 (2003).
  MedlineGoogle Scholar
• 35. Hegeto L, Caleffi-Ferracioli KR, Nakamura-Vasconcelos S et al. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis. Tuberculosis (Edinb.) 111, 35–40 (2018). • A prior study had shown synergistic activity between piperine and streptomycin.
  Medline CASGoogle Scholar
• 36. Balganesh M, Kuruppath S, Marcel N, Sharma S, Nair A. rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery. Antimicrob. Agents Chemother. 54(12), 5167–5172 (2010).
  Medline CASGoogle Scholar
• 37. Pérez J, Garcia R, Bach H et al. Mycobacterium tuberculosis transporter MmpL7 is a potential substrate for kinase PknD. Biochem. Biophys. Res. Commun. 348(1), 6–12 (2006).
  Medline CASGoogle Scholar
• 38. Siddiqi N, Das R, Pathak N, Banerjee S, Ahmed N. Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection 32(2), 109–111 (2004).
  Medline CASGoogle Scholar
• 39. Liu J, Shi W, Zhang S et al. Mutations in efflux pump Rv1258c (Tap) cause resistance to pyrazinamide, isoniazid, and streptomycin in M. tuberculosis. Front. Microbiol. 10, 216 (2019).
  MedlineGoogle Scholar
• 40. Fatsis-Kavalopoulos N, Roemhild R, Tang P-C, Kreuger J, Andersson DI. CombiANT: antibiotic interaction testing made easy. PLoS Biol. 18(9), e3000856 (2020).
  Medline CASGoogle Scholar